JP2023510199A5 - - Google Patents
Info
- Publication number
- JP2023510199A5 JP2023510199A5 JP2022540702A JP2022540702A JP2023510199A5 JP 2023510199 A5 JP2023510199 A5 JP 2023510199A5 JP 2022540702 A JP2022540702 A JP 2022540702A JP 2022540702 A JP2022540702 A JP 2022540702A JP 2023510199 A5 JP2023510199 A5 JP 2023510199A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062956469P | 2020-01-02 | 2020-01-02 | |
| US62/956,469 | 2020-01-02 | ||
| PCT/US2020/065799 WO2021138079A1 (en) | 2020-01-02 | 2020-12-18 | Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510199A JP2023510199A (ja) | 2023-03-13 |
| JPWO2021138079A5 JPWO2021138079A5 (https=) | 2023-12-22 |
| JP2023510199A5 true JP2023510199A5 (https=) | 2023-12-22 |
Family
ID=76687248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540702A Pending JP2023510199A (ja) | 2020-01-02 | 2020-12-18 | Ｐｄ－１アンタゴニスト、ｉｌｔ４アンタゴニストおよびレンバチニブまたはその塩を使用する組合せ癌治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230058779A1 (https=) |
| EP (1) | EP4084794A4 (https=) |
| JP (1) | JP2023510199A (https=) |
| KR (1) | KR20220137007A (https=) |
| CN (1) | CN115151258A (https=) |
| AU (1) | AU2020416715A1 (https=) |
| BR (1) | BR112022013143A2 (https=) |
| CA (1) | CA3166571A1 (https=) |
| MX (1) | MX2022008216A (https=) |
| WO (1) | WO2021138079A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021126906A1 (en) * | 2019-12-20 | 2021-06-24 | Merck Sharp & Dohme Corp. | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| US20250011453A1 (en) * | 2021-07-20 | 2025-01-09 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| WO2023077521A1 (en) * | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
| CN114191547A (zh) * | 2021-12-23 | 2022-03-18 | 中山大学 | 仑伐替尼与pd-1单抗联用在制备抗肝癌药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160093012A (ko) * | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| NZ733854A (en) * | 2015-02-26 | 2022-07-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| TWI796329B (zh) * | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
-
2020
- 2020-12-18 MX MX2022008216A patent/MX2022008216A/es unknown
- 2020-12-18 EP EP20910875.2A patent/EP4084794A4/en active Pending
- 2020-12-18 BR BR112022013143A patent/BR112022013143A2/pt not_active Application Discontinuation
- 2020-12-18 AU AU2020416715A patent/AU2020416715A1/en not_active Abandoned
- 2020-12-18 WO PCT/US2020/065799 patent/WO2021138079A1/en not_active Ceased
- 2020-12-18 US US17/790,543 patent/US20230058779A1/en active Pending
- 2020-12-18 KR KR1020227026590A patent/KR20220137007A/ko not_active Withdrawn
- 2020-12-18 CN CN202080098004.1A patent/CN115151258A/zh active Pending
- 2020-12-18 CA CA3166571A patent/CA3166571A1/en active Pending
- 2020-12-18 JP JP2022540702A patent/JP2023510199A/ja active Pending